HOME > BUSINESS
BUSINESS
- Meiji to Invest Up to US$20 Million in MPM BioImpact
January 14, 2025
- Japan Ethical Drug Sales Up 3.3% in November: Crecon
January 14, 2025
- Haihe Steps into Japan Oncology Space as CEO Sees Growth Potential
January 10, 2025
- Amitiza Most Heavily Pitched Medicine for Hospital Doctors in November: Intage
January 10, 2025
- FDA Accepts Re-Submission of Izervay to Buttress Label
January 10, 2025
- Keytruda Grabs Best-Seller Crown for 15th Month in December: Encise
January 10, 2025
- Padcev Broadens Label for Keytruda Combo in China: Astellas
January 9, 2025
- Fuso Grabs Japan Rights to Dimerix’s Kidney Disease Drug
January 8, 2025
- Mitsubishi Tanabe Gets Taiwan Rights for Rigel/Kissei’s ITP Drug
January 8, 2025
- Daiichi Sankyo to Transfer Avastin Biosimilar to Amgen in Japan
January 8, 2025
- BMS Taps Ex-Lilly Exec Katsuma as Japan Chief, Sugino as Asia-Pacific GM
January 7, 2025
- Biogen Japan Chief Hopes to Build Momentum in ALS Space Riding on Success with Qalsody
January 7, 2025
- Astellas’ Gastric Cancer Med Vyloy Approved in China
January 7, 2025
- Otsuka/Ionis’ HAE Drug Now under European Review
January 7, 2025
- J&J Bags Kaken’s STAT6 Inhibitor, Set to Take 6% Stake in Japan Firm
December 27, 2024
- Santen Files RVL Pharma’s Droopy Eyelid Drug in Japan
December 27, 2024
- Meiji Pharma Sues CDP Lawmaker for Defamation over Kostaive
December 26, 2024
- ASKA In-Licenses Another Women’s Health Drug from Insud
December 26, 2024
- Sandoz’s Rituximab Biosimilar Adds Pediatric ITP Indication
December 26, 2024
- Nihon Servier Files Glioma Drug Vorasidenib in Japan
December 25, 2024
ページ
Tariffs have been a defining feature of US trade policy under President Donald Trump’s second administration. Since Trump unveiled his “reciprocal” tariff policy in April 2025, the landscape has shifted repeatedly.In February 2026, the US Supreme Court invalidated tariffs imposed…
